Last edition
News about "Invasive Pneumococcal Disease (IPD)"
US FDA Approves Additional Indication for CAPVAXIVE
The US Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for children and adolescents aged 2-17 years at increased risk of pneumococcal disease, broadening protection against serious pneumococcal infections in vulnerable pediatric populations.
Invasive Pneumococcal Disease (IPD) | 20/06/2026 | By News Bureau | 108
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members